Allogene Therapeutics (ALLO) EBITDA Margin (2021 - 2026)
Allogene Therapeutics (ALLO) posted EBITDA Margin of 315927.27% for Q1 2024, up 22.05% sequentially from 405280.95% in Q4 2023, and up 1437939.0% YoY from N/an in Q2 2023.
Allogene Therapeutics (ALLO) EBITDA Margin (2021 - 2026) Analysis & Trends
Allogene Therapeutics has reported EBITDA Margin for 4 years, with the latest figure at 315927.27% in Q1 2024.
- Quarterly EBITDA Margin rose 1437939.0% year-over-year to 315927.27% in Q1 2024, while the trailing twelve-month figure through Dec 2024 was 1241813.64% (down 89682732.0% YoY) and the FY2024 annual result came in at 1241813.64%, down 89682732.0% from the prior year.
- EBITDA Margin advanced to 315927.27% in Q1 2024 per ALLO's latest filing, from 405280.95% in the prior quarter.
- Over five years, EBITDA Margin peaked at 2.26% in Q4 2021 and troughed at 405280.95% in Q4 2023.
- A 4-year average of 232707.56% and a median of 286345.45% in 2023 frame the typical range for EBITDA Margin.
- The widest YoY moves for EBITDA Margin: up 4171705 bps in 2022, down 37075226 bps in 2022.
- Over 4 years, EBITDA Margin stood at 2.26% in 2021, then plunged by 16431036 bps to 370750.0% in 2022, then dropped by 9 bps to 405280.95% in 2023, then advanced by 22 bps to 315927.27% in 2024.
- According to Business Quant data, EBITDA Margin over the past three periods registered 315927.27%, 405280.95%, and 286345.45% for Q1 2024, Q4 2023, and Q3 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,569,866.34% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Allogene Therapeutics | 707.96 Mn | 707.96 Mn | - | -1,011.21% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1,011.21% |
| Mar 31, 2024 | -315,927.27% |
| Dec 31, 2023 | -405,280.95% |
| Sep 30, 2023 | -286,345.45% |
| Jun 30, 2023 | -366,090.91% |
| Mar 31, 2023 | -330,306.67% |
| Dec 31, 2022 | -370,750.00% |
| Sep 30, 2022 | -305,596.30% |
| Jun 30, 2022 | -119,712.50% |
| Mar 31, 2022 | -205,164.10% |
| Dec 31, 2021 | 2.26% |
| Sep 30, 2021 | -158,510.20% |
| Jun 30, 2021 | -161,429.55% |
| Mar 31, 2021 | -86.58% |